Writing Group Disclosures

Writing Group MemberEmploymentResearch GrantOther Research SupportSpeakers’ Bureau/HonorariaExpert WitnessOwnership InterestConsultant/Advisory BoardOther
Dariush MozaffarianTufts UniversityNoneNoneBunge*; Haas Avocado*NoneNoneAmarin*; Life Sciences Research Organization*; AstraZeneca*; Boston Heart Diagnostics*; GOED*; Unilever North America*; Elysium Health*None
Emelia J. BenjaminBoston University School of MedicineNIH; NHLBINoneNoneNoneNoneNoneNone
Alan S. GoKaiser PermanenteCSL Behring; Sanofi; iRhythmNoneNoneNoneNoneNoneNone
Donna K. ArnettUniversity of Alabama at BirminghamNoneNoneNoneNoneNoneNoneNone
Michael J. BlahaJohns Hopkins University School of MedicineAetnaNoneNoneNoneNonePfizer*; Novartis*American College of Cardiology*
Mary CushmanUniversity of Vermont, Department of MedicineNoneNoneNoneNoneNoneNoneNone
Sandeep R. DasUniversity of Texas Southwestern Medical CenterNoneNoneNoneNoneNoneNoneNone
Sarah de FerrantiChildren’s Hospital, BostonNoneNoneNoneNoneNoneNoneNone
Jean-Pierre DesprésCentre de recherché de I’Institut universitaire de cardiologie et de pneumologie de QuebecNoneNoneAbbott Laboratories; AstraZeneca; GlaxoSmithKline; Merck; Pfizer Canada IncNoneNoneAbbott Laboratories; Sanofi; Torrent Pharmaceuticals LtdNone
Heather J. FullertonUniversity of California, San FranciscoNIH; AHANoneNoneNoneNoneNoneNone
Virginia J. HowardUniversity of Alabama at BirminghamNoneNoneNoneNoneNoneNoneNone
Mark D. HuffmanNorthwestern University School of MedicineWorld Heart Federation; JR Alberts Foundation; NHLBINoneNoneNoneNoneNoneNone
Carmen R. IsasiAlbert Einstein College of MedicineNoneNoneNoneNoneNoneNoneNone
Monik C. JiménezBrigham and Women’s HospitalNoneNoneNoneNoneNoneNoneNone
Suzanne E. JuddUniversity of Alabama at BirminghamNoneNoneNoneNoneNoneNoneNone
Brett M. KisselaUniversity of Cincinnati Academic Health CenterNoneNoneNoneNoneNoneNoneNone
Judith H. LichtmanYale School of Public HealthNoneNoneNoneNoneNoneNoneNone
Lynda D. LisabethUniversity of MichiganNoneNoneNoneNoneNoneNoneNone
Simin LiuBrown UniversityNoneNoneNoneNoneNoneNoneNone
Rachel H. MackeyUniversity of PittsburghNoneNoneNoneNoneNoneNoneNone
David J. MagidKaiser Permanente of Colorado Institute for Health ResearchNIH*; PCORI*; Angen*; NHLBI*; NIA*NoneNoneNoneNoneNoneNone
Darren K. McGuireUniversity of Texas–Southwestern Medical CenterNoneNoneNoneNoneNoneAstraZeneca; Merck*; Takeda*; Novo Nordisk; Boerhinger Ingelheim; Sanofi Aventis; Glaxo Smith Kline*; Lexicon; Regeneron*; Janssen; Eli Lilly*None
Emile R. Mohler IIIUniversity of Pennsylvania Vascular Medicine HospitalNoneNoneNoneNoneCytovas*NoneNone
Claudia S. MoyNIH/NINDSNoneNoneNoneNoneNoneNoneNone
Paul MuntnerUniversity of Alabama at BirminghamAmgen IncNoneNoneNoneNoneNoneNone
Michael E. MussolinoNIH/NHLBINoneNoneNoneNoneNoneNoneNone
Khurram NasirBaptist Health Medical Group Center for Healthcare Advancement & OutcomesNoneNoneNoneNoneNoneRegeneron*None
Robert W. NeumarUniversity of MichiganNoneNoneNoneNoneNoneNoneNone
Graham NicholUniversity of Washington–Harborview Center for Prehospital Emergency CareSotera Wireless–Patient Health and Resuscitation Surveillance (PHAROS) Network, PI*; Food and Drug Administration, Cardiac Science Corp, Heartsine Technologies Inc, Philips Healthcare Inc, Physio-Control Inc, Zoll Medical Inc*; National Heart, Lung, and Blood Institute–Resuscitation Outcomes Consortium Data Coordinating Center, U01 HL077863-07, Co-PI; NeuroproteXeon Inc–Xenon After Resuscitation from Ventricular Fibrillation (Xena) Trial, PINoneNoneNoneNoneNoneUniversity of Washington–Leonard A Cobb Medic One Foundation Endowed Chair in Prehospital Emergency Care
Latha PalaniappanStanford UniversityNoneNoneNoneNoneNoneNoneNone
Dilip K. PandeyUniversity of Illinois at ChicagoCenters for Disease Control and Prevention (CDC)NoneNoneNoneNoneNoneUniversity of Illinois
Mathew J. ReevesMichigan State UniversityNoneNoneNoneNoneNoneNoneNone
Carlos J. RodriguezWake Forest UniversityNoneNoneNoneNoneNoneNoneNone
Wayne RosamondUniversity of North Carolina School of Public HealthNoneNoneNoneNoneNoneNoneNone
Paul D. SorlieNational Heart, Lung, and Blood InstituteNoneNoneNoneNoneNoneNoneNone
Joel SteinColumbia UniversityNexstim*; Tyromotion, Inc*; Myomo, Inc*; Columbia – Coulter Translational Research Partnership*; National Science Foundation*; PCORI*; McDonnell Foundation*; New York State Spinal Cord Injury Research Program*NoneNoneNoneNoneMyomo*None
Amytis TowfighiUniversity of Southern CaliforniaNoneNoneNoneNoneNoneNoneNone
Tanya N. TuranMedical University of South CarolinaNoneNoneNoneNoneNoneNoneNone
Salim S. ViraniMichael E. DeBakey VA Medical CenterAmerican Heart Association; American Diabetes Association; Department of Veterans Affairs; Baylor College of Medicine Center for Globalization Grant; Baylor College of Medicine Academy of Distinguished Educators*NoneNoneNoneNoneNonePatient and Provider Assessment of Lipid Management (PALM) Registry at Duke Clinical Research Institute (DCRI)*
Daniel WooUniversity of CincinnatiNoneNoneNoneNoneNoneNoneNone
Robert W. YehMassachusetts General HospitalNoneNoneNoneMerck (defendant, 2015, Clinical Trial Execution)NoneNoneNone
Melanie B. TurnerAmerican Heart AssociationNoneNoneNoneNoneNoneNoneAmerican Heart Association
  • This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

  • * Modest.

  • Significant.